anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute necrotizing esophagitis (ANE) is a rare and potentially life-threatening complication of diabetic ketoacidosis (DKA). While its association with DKA is established, specific clinical characteristics that predict ANE in DKA patients remain less understood. This study aimed to identify these characteristics by analyzing data from 30 DKA patients admitted from January 2018 to September 2022. Seven patients in this study presented with ANE, forming the ANE group. The remaining 23 constituted the non-ANE group. We compared the clinical parameters and computed tomography (CT) between the groups. The mean age of participants was 57.7 ± 20.4 years, and their mean HbA1c was 11.1 ± 3.3%. Notably, ethanol intake was significantly higher in the ANE group (44.4 ± 25.4 g/day) compared to the non-ANE group (6.8 ± 14.0 g/day; p = 0.013). Additionally, sodium-glucose transport protein 2 inhibitor use was significantly more prevalent in the ANE group (p = 0.013). Gastrointestinal symptoms were also significantly more pronounced in the ANE group, with vomiting occurring in 85.7% of patients compared to only 13.0% in the non-ANE group. Admission CT scans revealed further distinguishing features, with the ANE group showing significantly higher rates of esophageal wall thickening, intra-esophageal effusion, and calcification of the celiac artery origin (p < 0.0001, 0.0038, 0.0038, respectively). In conclusion, our study suggests that heavy alcohol consumption and strong gastrointestinal symptoms in DKA patients warrant a heightened suspicion of ANE. Early consideration of CT or upper gastrointestinal endoscopy is recommended in such cases.
Spatial regulation of gingival microcirculation has not been revealed yet. Although this could be an important mechanism to protect gingiva as it is exposed to mechanical, chemical, thermal etc. irritation during whole life. It is especially important during flap surgery. Laser Speckle Contrast Imaging (LSCI) is novel non-invasive method with high spatio-temporal resolution, therefore it allows us to study remote effect of local vasoconstriction such as spreading vasoconstriction in human gingiva.

The epinephrine is a daily used vasoconstrictor material in dentistry and it will be used to trigger remote effect on gingiva. Epinephrine in 1 mg/ml concentration. Solution will be dropped on the gingiva at tooth 12 in a fabricated leakage proof well attached to 2mm above the marginal gingiva in group "A". The solution will be dropped on the surface of tooth 12 next to the sulcus into the well in case of group "B". The changes of the blood flow will be monitor at the test side with surrounding gingival area by LSCI. The control side in each case will be - appropriately to the test side - at tooth 21 with phisiologocal saline.
This invention is a method for the treatment of macular degeneration, and in particular, age-related macular degeneration. The method entails application of an effective amount of Transforming Grtowth Factor-β (TGF-β) to the area of the retina requiring treatment. In one treatment regime, the TGF-β is applied locally over the area of the macula following vitrectomy of the eye. In a second treatment regime, a portion of the total TGF-β dose is injected into the subretinal space and the remainder of the dose is applied locally over the area of the macula. This second treatment regime is also performed during or following vitrectomy of the eye. Alternative routes of administration of TGF-β include intrascleral and suprachoroidal administration.
A growing body of evidence highlights the crucial role of metabolic reprogramming in activated immune cells, significantly contributing to both the initiation and progression of neuroinflammation and neurodegenerative diseases. The voltage-gated H channel (Hv1) has been reported to be involved in microglial activation and acts as a key driver of neuroinflammation. This study aimed to explore how Hv1-mediated metabolic reprogramming contributes to neuroinflammation and to assess the therapeutic potential of the Hv1 inhibitor 2-GBI in a model of lipopolysaccharide (LPS)-induced neuroinflammation. We investigated the influence of 2-GBI on the generation of ROS, metabolic reprogramming, and pro-inflammatory mediator production in vitro and examined the therapeutic effect of 2-GBI on microglial activation and hippocampal neuroinflammation in vivo. The results indicated that 2-GBI attenuated the LPS-induced pro-inflammatory response and aerobic glycolysis in microglia, specifically mitigating HIF1α-mediated upregulation of glycolysis. 2-GBI exerted a protective effect against LPS-induced neuroinflammation through HIF1α pathway-regulated aerobic glycolysis. Using a transwell coculture system, we demonstrated that 2-GBI reversed PC12 cell death caused by BV2-mediated neuroinflammation. In vivo experiments further suggested that 2-GBI mitigated neuroinflammatory processes and cognitive dysfunction via microglial metabolic reprogramming. Collectively, our results highlight the potential of Hv1 inhibition as a therapeutic strategy for alleviating LPS-induced neuroinflammation by modulating microglial metabolic reprogramming.
The project was preceded by a pilot verification to select an appropriate approach for implementing the research design, including the development of a new VR application that took into account current technological advancements in this field. As part of the pilot verification, a custom application was created based on experiences with existing VR applications designed for therapeutic purposes for burn trauma patients in collaboration with Space s.r.o. Patients meeting the selection criteria (e.g., extent of burns, consent to participate in the study, and other relevant factors) were included in the study after the second dressing change in the dressing room. It was during these dressing changes that procedural pain occurred, first during the removal of old dressings and then during the removal of necrotic tissue and the application of new dressings. Each of these painful procedures was divided into two parts: 1) removal of old dressings; 2) removal of necrotic tissue and application of new dressings. In the study, pain sensation was repeatedly measured using the NPRS (Numeric Pain Rating Scale) and BSPAS (Burns Specific Pain Anxiety Scale) for both parts in at least 30 patients. Before each dressing change, it was randomly determined whether the VR would be used during the first part (removal of old dressings) or only during the second part (removal of necrotic tissue and application of new dressings). Additionally, the part involving VR was further assessed using a short immersion inventory, the Igroup Presence Questionnaire (IPQ). In the end, it was possible to evaluate the effect of VR on pain management during dressing changes in patients with burn trauma. The investigators will continue to measure several variables. The feeling of nausea will be assessed in a virtual environment on an ordinal scale from 0, indicating no nausea, to 10, indicating the worst imaginable nausea. Age will be recorded and categorized into six ordinal groups ranging from 18 to 70 years and older. The type of medications participants are currently taking will be recorded, categorized into six levels, including options ranging from none to five types of medications, such as strong opioids and analgesics. The total body surface area (TBSA) burned will be measured, with categories ranging from 0.4% to 45% or more. Additionally, the investigators will assess how the burn was caused, with categories including electro trauma, scalding, chemical trauma, frostbite, and flame burns. They will also evaluate participants\' gaming and VR experience, determining whether participants consider themselves gamers, play games regularly, or have personal experience with virtual reality. These measurements aim to provide a detailed understanding of the participants´ conditions and their responses during the study.
Approximately 10 minutes for the child. Inhaler medication will be given with a mask that lasts. The child will be allowed to play with the matching cards 2-3 minutes before starting the drug treatment and will then be encouraged to play throughout the procedure. Vital signs (pulse, blood pressure, SPo2, respiration) before and after the application, Child Fear Scale will be evaluated by the researcher and the parent and recorded in the intervention follow-up form by the researcher.
The present invention relates to an injection solution with red sage root and ligustrazine freezing dry powder and a preparation method of the injection solution, and the present invention belongs to the technical field of medicine. The present invention is used for solving the problems of unstable quality and inconvenient transportation, carrying and storage of the injection solution. The present invention has the technical scheme that the injection solution is in a powdery shape and is composed of red sage root extract, ligustrazine hydrochloride and an appropriate filling agent; the present invention has the components of red sage root raw medicinal material to the ligustrazine hydrochloride to the filling agent of 400 to 1100: 50 to 150: 0 to 200. The preparation method comprises the processes of red sage root liquid extraction, physic liquor configuration, freeze drying, package, etc. The injection solution of the present invention has the advantages of reliable therapeutic effect, stable quality, convenient application and long effective period. The finished product of the injection solution is honeycombed formless powder with loose texture; the powder has a porous structure, so the powder is easily dissolved in water; the powder is rapidly dissolved after water is added and restores the primary characteristics of physic liquor. The preparation method of the present invention can well remove impurities, reduce anaphylactic reaction and farthest reserve effective constituents to increase the therapeutic effect of the product and reduce the secondary reaction.
Participants in this group were exposed to 4 audio recordings applying standardized pressure. Unlimited time.
Unilateral absence of a pulmonary artery (UAPA) is an uncommon congenital anomaly. Among the rarer conditions, UAPA with lung cancer has been previously reported in 13 cases; however, there remains controversy regarding the surgical approach and precautions. Herein, we present a case study of a 56-year-old female patient who was incidentally diagnosed with a nodule in the right lower lobe of the lung during a routine physical examination and subsequently found to have an absent right pulmonary artery upon preoperative evaluation. A wedge resection of the right lower lobe was performed as treatment. Postoperative pathology confirmed invasive adenocarcinoma (pT1N0M0). We provide a narrative review of existing literature on these patients and discuss optimal surgical management strategies.
Chromosomal trisomy presents with a range of clinical manifestations, from subtle to life-threatening conditions that include trisomy 16, the most common aneuploidy in first trimester abortions. Most cases are linked to maternal complications and spontaneous abortions, typically detected prenatally. Infants who survive with trisomy 16 often have mosaic variants and may exhibit various anatomical and metabolic abnormalities, though a trisomy 16 diagnosis does not guarantee the presence of such abnormalities. We share the case of a 15-year-old boy who has mosaic trisomy 16. He was diagnosed after birth and showed mild symptoms without any major anatomical issues. However, he did experience several metabolic problems, such as insulin resistance, obesity, hormonal imbalances, and vitamin D deficiency. This report highlights the diverse clinical characteristics of trisomy 16, comparing them to previously reported cases.
Spinal cord injury (SCI) often results in complete or partial paralysis below the level of lesion, having a profound physical, psychological and socioeconomic impact on the affected person's life. Between the different approaches for the rehabilitation of SCI, we can find robot therapy. Robot-assisted gait training has emerged as a promising therapy for improving walking ability, balance and motor function in neurological patients. The underlying principle of this therapy is based on the execution of repetitive and task-specific training able to generate appropriate afferent inputs, activating the central pattern generators in the lumbosacral spinal cord. Another novel therapy is the use of transcutaneous spinal cord stimulation (tSCS), applied through self-adhesive electrodes in the skin. tSCS activates similar mechanisms than epidural stimulation and is able to stimulate the spinal locomotor circuits in SCI patients. It allows the activation of rhythmic, flexo-extension movements in the paralyzed lower limbs.

The aim of this study is to analyze the feasibility, safety and efectiveness of a program of 20 sessions of 30 Hz-tSCS applied over T11-12 intervertebral space combined with Lokomat training in patients with incomplete SCI.
Experimental group (n= 39) 3M Cavilon ® protective spray film + FBM - skin cleaning and pain scale application will be performed and after laser application in 8 points of the affected perineum region, these applications will occur 1 x a day every 24 hours for three days. Skincare will be maintained with 3M Cavilon ® Cleansing Solution and the use of 3M Cavilon ® Protective Spray Film. The photographic record of the lesion will be performed on days 0 and 3, 5 and 7 days of treatment. To monitor the participants and observe the recovery and obtainment of skin healing. It will be used the Globaid tool that will be applied in both groups.
Familial exudative vitreoretinopathy (FEVR) is linked to disruption of the Norrin/Frizzled-4 signaling pathway, which plays an important role in retinal angiogenesis. Severe or complete knock-down of proteins in the pathway also causes syndromic forms of the condition. Both heterozygous and biallelic pathogenic variants in the FZD4 gene, encoding the pathway's key protein frizzled-4, are known to cause FEVR. However, it is not clear what effect different FZD4 variants have, and whether extraocular features should be expected in those with biallelic pathogenic FZD4 variants. Biallelic FZD4 variants were found in a young boy with isolated, severe FEVR. His parents were heterozygous for one variant each and reported normal vision. In-vitro studies of the two variants, demonstrated that it was the combination of the two which led to severe inhibition of the Norrin/Frizzled-4 pathway. Our observations demonstrate that biallelic FZD4-variants are associated with a severe form of FEVR, which does not necessarily include extraocular features. In addition, variants causing severe FEVR in combination, may have no or minimal effect in heterozygous parents as non-penetrance is also a major feature in dominant FZD4-FEVR disease. This underscores the importance of genetic testing of individuals and families with FEVR.
A multi-center, open-label, phase II clinical study of metformin in up to 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index tumour (0.5-1 cm) selected ane measured during cystoscopy. All patients will receive metformin orally at doses up to 1500 mg twice daily. Metformin treatment will start directly after informed consent is obtained. After 3 months of metformin treatment, the effect of metformin on the index lesion is evaluated by performing a transurethral resection of the bladder tumour under anaesthesia. Residual tumour, if present at this evaluation, will be resected. In case of complete disappearance of the index lesion the former tumour area will be biopsied.
LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days.
Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of MultiHance administration and resolved with prompt emergency treatment.

Prior to MultiHance administration, ensure the availability of personnel trained and medications to treat hypersensitivity reactions. If such a reaction occurs stop MultiHance and immediately begin appropriate therapy. Additionally, consider the risk for hypersensitivity reactions, especially in patients with a history of hypersensitivity reactions or a history of asthma or other allergic disorders. Observe patients for signs and symptoms of a hypersensitivity reaction during and for up to 2 hours after MultiHance administration.
PURPOSE:To obtain a lipid metabolism improver having immediate effects free from side effects, containing a calcium hexose phosphate as an active ingredient. CONSTITUTION:A calcium hexose phosphate (e.g. calcium glucose-1-phosphate) and, if necessary, a given carrier for preparation, excipient, etc., are pharmaceuti cally manufactured by a conventional procedure to give the aimed substance. The substance can be made into tablets, granules, capsule agents, oral adminis tration agent, etc. A dose is 0.1-20g, preferably 1-10g calculated as calcium hexose per person daily. Acute toxicity of mouse of calcium glucose-1-phosphate is >=15,000mg/kg and the substance is extremely safe. Since the substance extremely lowers concentration of serum cholesterol, the substance is effective as a preventive and remedy for myocardial infarction, ischemic heart disease and hypercholesterolemia.
A liquid antimicrobial composition is provided for disinfecting human or animal skin, particularly where it is desired to disinfect drug-resistant organisms. The composition comprises a cationic microbiocide that disrupts cell membranes and a cationic branched polymer that is capable of inhibiting the efflux pump mechanism of said cell membranes. The cell membrane disrupting cationic microbiocides are preferably any one or a combination of chlorohexidine, polymeric biguanides, octenidine dihydrochloride and quaternary ammonium compounds. The provided branched polymers are capable of binding to and disrupting the cell membrane of microorganisms, inhibiting or disrupting the efflux pump mechanism of the cells, thereby preventing microbial strains from becoming tolerant to the increasingly common cationic microbiocides that disrupt the cell membrane, especially when the microbiocides comprise chlorhexidine. The branched polymer is preferably a 0-to 3-generation branched polymer comprising any one of poly (propylene imine) functionalized quaternary ammonium, polylysine, a branched polymer having sugar-based surface groups, and a Polyamidoamine (PAMAM) branched polymer, or a combination thereof. The composition is preferably in the form of an aqueous or hydroalcoholic solution, dispersion or emulsion that can be adsorbed by the wipe.
Propofol at a dose of 2mg/kg will be administered I.V. .
Adults with COPD (FEV1\<80%). Intervention as for all groups but with added pulmonary rehabilitation focus.
Provided are therapeutic combinations, pharmaceutical compositions, and pharmaceutical kits comprising bioactive molecules from fungi, plants, and algae. In some embodiments, the fungi are from any psilocybin-producing fungi, such as from Psilocybe spp. fungi. In some embodiments, the plants are from either or both of the Cannabis and Dipteryx genera. In some embodiments, the algae may be marine algae, such as from the family Bangicaeae, including the Pyropia and Porphyra genera. Methods of producing the disclosed combinations, compositions, and kits are also provided, such as using natural, biosynthetic, or synthetic means. Further provided are methods of using the disclosed combinations, compositions, and kits in treatment, and in particular for movement disorders, such as for Parkinson's disease, and the disclosed combinations are demonstrated to provide significant advantages in the treatment thereof.
Disclosed is a hepatoprotective traditional Chinese medicine composition, extract and pharmaceutical use thereof. The composition comprises  Morinda officinalis  How,  Ganoderma lucidum  (Leyss. Ex Fr.) Karst.,  Astragalus membranaceus  (Fisch) Bge. Var.  monghlicus  (Bge) Hsiao,  Ranunculus ternatus  Thunb.,  Sophora flavescens  Alt. and  Salvia miltiorrhiza  Bge. The composition and extract thereof may be used for treating liver injury, hepatitis, hepatic fibrosis, hepatic cirrhosis or liver cancer, and they may also be used as a vaccine adjuvant or an immunomodulator.
OBJECTIVE: In this study, we describe the incidence, sites of valve injury, and the influence of aortic valve regurgitation (AR) on outcomes of septal myectomy for obstructive hypertrophic cardiomyopathy.
METHODS: We analyzed patients who underwent transaortic septal myectomy for obstructive hypertrophic cardiomyopathy from 2001 to 2022. The primary study end point was incidence of procedure-related AR, defined as the need for an unplanned aortic valve (AV) procedure or new-onset moderate AR on early postoperative echocardiography.
RESULTS: There were 2807 patients who underwent transaortic septal myectomy for hypertrophic cardiomyopathy and had pre- and postoperative transthoracic echocardiograms. Procedure-related AR was observed in 55 (2%) patients; 27 (1%) required unplanned AV procedures at the time of myectomy, and 29 (1%) additional patients developed moderate AR postoperatively. During follow-up, 9 total patients underwent late AV reoperation, 1 patient who developed new moderate AR postoperatively required late AVR due to severe calcific AS, and none of the patients who had unplanned AV procedures required late reoperation. The overall cumulative incidence of AV reoperation at 10 and 15 years was 1% and 5%. The predicted probability of moderate or severe AR at 5 and 10 years was 1.4% and 1.8%, respectively. There was no difference in survival comparing patients with or without early postoperative mild or worse AR (P = .69).
CONCLUSIONS: Procedure-related AR was observed in 2% of patients undergoing transaortic septal myectomy, and unplanned AV procedures were necessary for half of these patients. Intraoperative identification and valve repair mitigate the impact of cusp injury on late reintervention and survival.
PURPOSE:To obtain a new compound useful for treating cancerous diseases as adjuvant for cancer chemotherapy. CONSTITUTION:A compound of the formula [R1 is lower alkyl or aralkyl; R2 and R4 are S or O; R3 is H, lower alkyl, lower alkylthio, or Sm(CH2)nN.R5.R6 (m is 0 or 1; (n) is 1-6; R5 and R6 are lower alkyl)]. The compound is obtained by reacting an ethylenediamine derivative with ethyl carboxycarbamate in a solvent (e.g. xylene) at 100-150 deg.C. (in the case where R2 and R4 are O and R3 is H). The compound of the formula is contained as an active ingredient, has promoting action on accumulation of an anti-cancer medicine to a cell having multiple anticancer medicine resistance and is pharmaceutically manufactured into an adjuvant for cancer chemotherapy. A dose of the compound of the formula is orally 5-300mg calculated as weight of the active ingredient daily.
Crystal arthropathies patients. \>18 years Imaging studies: CT and X-ray/MRI/US Physical examination by the rheumatologist and laboratory tests which are conventionally necessary for the diagnosis.
Group 1 patients receive "Sexual Nursing Care," involving personalized counseling by a nurse to address sexual dysfunctions post-stroke. The intervention includes partner involvement to foster new intimacy, sexual education, and exercises. Four 45-minute outpatient sessions with the nurse and partner are provided. Any emerging issues requiring diagnostic investigation will be communicated to the referring specialist.